Latest News

Study: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection.

read more

Study: Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people

The clinical impact of the new
SARS-CoV-2 lineage B.1·1.7 on children
and young people (aged 18 years or
younger) regarding acute respiratory
COVID-19 is yet to be fully defined.
Media reports of increases in admissions
to hospital and more serious illness in
children and young people have resulted
in public confusion and implicated the
B.1.1.7 variant as a more pathogenic
infection within this group. This
uncertainty has necessitated a public
statement from the Royal College of
Paediatrics and Child Health.

read more

Report: More than eight-in-ten Americans get news from digital devices

The transition of news from print, television and radio to digital spaces has caused huge disruptions in the traditional news industry, especially the print news industry. It is also reflected in the ways individual Americans say they are getting their news. A large majority of Americans get news at least sometimes from digital devices, according to a Pew Research Center survey conducted Aug. 31-Sept. 7, 2020.

read more

SARS-CoV-2 mutation T478K spreading at alarming speed in Mexico

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern are characterized by mutations in the receptor-binding domain and more significant spike protein that enhance virulence by increasing the affinity of this region to the target ACE2 receptor found on the surface of cells, and could potentially better evade vaccine-generated antibodies that are specific to the wildtype spike protein. 

read more

Study: COVID-19, Fake News, and Vaccines: Should Regulation Be Implemented?

We analysed issues concerning the establishment of compulsory vaccination against COVID-19, as well as the role of misinformation as a disincentive—especially when published by health professionals—and citizen acceptance of measures in this regard. Data from different surveys revealed a high degree of hesitation rather than outright opposition to vaccines. 

read more

Study: Survivorship after COVID-19 ICU stay

Our understanding of the epidemiology of the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) infection and associated COVID-19 illness continues to evolve. Statistics from early in the pandemic indicate that ~1 in 5 infected individuals are hospitalized, and 1 in 10 may be admitted to an intensive care unit (ICU), with most of these critically ill patients experiencing acute respiratory distress syndrome (ARDS) and requiring mechanical ventilation. 

read more

Study: Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

Growing evidence shows that a significant number of patients with COVID-19 experience prolonged symptoms, known as Long COVID. Few systematic studies exist which investigate this population, and hence, relatively little is known about the range in symptom makeup and severity, expected clinical course, impact on daily functioning, and expected return to baseline health.

read more

Report: The Impact of COVID-19 on Logistics

Logistics firms, which are involved in the
movement, storage, and flow of goods, have been directly affected by the COVID-19 pandemic. As an integral part of value
chains, both within and across international borders, logistics firms facilitate trade and commerce and help businesses get their products to customers. Supply chain disruptions to the sector caused by the pandemic could, therefore, impact competitiveness, economic growth, and job creation.

read more

Study: COVID-19 Detection Kits Market Size, Share & Trends Analysis Report By Product, By Sample Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab), By Mode, By End Use, And Segment Forecasts, 2020 – 2027

The global COVID-19 detection kits market size is valued at USD 3.28 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.05% from 2021 to 2027. Several nations are engaged in the development of kits and apps along with tracking programs for mass testing. The COVID-19 smartphone app established by Britain uses Bluetooth signals to identify COVID-19 affected individuals. This centralized approach also provides detailed data pertaining to the symptoms and risks of infection. Such initiatives accelerate the detection of infected patients, which further impacts revenue growth. Manual testing, pitfalls in read-out timing, and visual reporting lead to uncertain outcomes compared to automated tests. In regard to this, QIAGEN has developed an easy-to-use digital test, known as Access Anti-SARS-CoV-2 Total, in August 2020. This serology test is conducted on a portable digital device to offer reliable results in 10 minutes and mitigates such risks. The availability of smart testing solutions is expected to boost market growth in the near future.

read more

Global Telehealth Market Size 2021 Rise at 26.5% CAGR, Will Reach USD 475.50 Billion By 2026: Facts & Factors

According to Facts and Factors market research report, the Global Telehealth Market size & share revenue is expected to grow from USD 62.45 Billion in 2020 to reach USD 475.50 Billion by 2026, at 26.5% annual CAGR growth during forecast period of 2021-2026. The top market companies profiles included in report with their sales, revenues and strategies are American Well, MDLIVE, Inc., Teladoc Health, Inc., Doctor on Demand, Inc., Dictum Health, Inc., Grand Rounds, Inc., OpenTelehealth, Medtronic and others.

read more

The Pfizer/BioNTech Covid-19 Vaccine Is Less Effective Against The South African And UK Variants Than Against The Original Virus, According To A New “Real-World” Study From Israel

The novel mRNA vaccines of Moderna and Pfizer/BioNTech are among the most effective of all the developed vaccines at preventing infection and disease. For that, we are all grateful. But even the best vaccines fail to protect some people some of the time. The clinical trial data from both the Pfizer/BioNTech and the Moderna shows they are around 95% effective, which means that 5% of those fully vaccinated are still at risk for infection even a short time following the complete dose, when the vaccines are thought to be maximally effective. 

read more